New antibody drug aims to ease lung blood pressure
NCT ID NCT07318597
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 6 times
Summary
This study tests an experimental drug called REGN13335 in 99 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive either the drug or a placebo, on top of their usual PAH medications. The goal is to see if REGN13335 safely lowers lung blood pressure and improves heart function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN13335 (an antibody that blocks a protein called PDGF-B)
- What this could lead to
- If it works, this could lead to a new treatment option for people with pulmonary arterial hypertension, helping to lower blood pressure in the lungs and improve heart function.
- What could go wrong
- This is a mid-stage trial with only 99 participants, so results may not apply to everyone. The drug is still experimental, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
RECRUITINGSeoul, Songpa-gu, 05505, South Korea
-
Clinic of University Greifswald
RECRUITINGGreifswald, 17485, Germany
-
Gachon University Gil Medical Center
RECRUITINGNamdong-gu, Incheon, 21565, South Korea
-
H.U.B. Erasme Hospital
RECRUITINGBrussels, 1070, Belgium
-
Hopital Bicetre
RECRUITINGLe Kremlin-Bicêtre, 94275, France
-
Hospital Clinic, Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Hospital Universitario Costa del Sol
RECRUITINGMarbella, Malaga, 29603, Spain
-
Hospital Vall d'Hebron
RECRUITINGBarcelona, Catalonia, 08035, Spain
-
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITINGLondon, W12 0HS, United Kingdom
-
Mater Misericordiae Ltd
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
-
Oddzial Kardiologiczny
RECRUITINGLodz, Łódź Voivodeship, 93487, Poland
-
P. Stradins Clinical University hospital
RECRUITINGRiga, LV1002, Latvia
-
Royal Hobart Hospital
RECRUITINGHobart, Tasmania, 7000, Australia
-
Royal United Hospitals Bath NHS Foundation Trust
RECRUITINGBath, BA1 3NG, United Kingdom
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
-
UZ Leuven
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium
-
Universitatsklinikum Halle
RECRUITINGHalle, Saxony-Anhalt, 06120, Germany
-
Universitatsmedizin Mainz
RECRUITINGMainz, 55131, Germany
-
University Clinical Hospital in Poznan - Early Phase Unit
RECRUITINGPoznan, Greater Poland Voivodeship, 61-848, Poland
-
University Hospital Salamanca
RECRUITINGSalamanca, 37007, Spain
-
University Hospital in Bialystok
RECRUITINGBialystok, Podlaskie Voivodeship, 15-276, Poland
-
University hospital 12 de octubre
RECRUITINGMadrid, 28041, Spain
-
University of Colorado Denver
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check